Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Transference in Pregnancy: RheumMadness 2022 TNFi in Cord Blood Scouting Report

University of Chicago Medicine: Lauren He, MD; & Cuoghi Edens, MD  |  Issue: May 2022  |  March 2, 2022

Editor’s note: RheumMadness is the place for everyone crazy about rheumatology to connect, collaborate, compete and learn together. During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to read the scouting reports for each concept team. These reports are written by rheumatology fellows from 13 programs throughout the U.S.

Don’t forget to submit your RheumMadness 2022 bracket by March 25. The more your picks match those of our Blue Ribbon Panel of rheumatologists, the more points you get. Learn more about the panel and how the brackets work online.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Connect with RheumMadness by subscribing to the podcast and joining the conversation on Twitter, #RheumMadness. Learn more on the RheumMadness website.

Region: People

Team: TNFi in Cord Blood

Wardell Stephen “Dell” Curry Sr. and Steph Curry, Tim Hardaway and Tim Jr., Joe and Kobe Bryant—all exemplify athletic skill passed from parent to child. In this scouting report, we explore a different type of transference to help patients and providers understand the safety of tumor necrosis factor (TNF) inhibitor use during pregnancy.

The 2016 EULAR Points to Consider for Use of Anti-Rheumatic Drugs Before Pregnancy, and During Pregnancy and Lactation support the use of TNF inhibitors  during the first half of pregnancy.1 Although the EULAR taskforce synthesized existing data to develop much-needed recommendations, the analysis was limited by the need to focus on widely studied end points, such as congenital malformations. Quantifying drug levels transferred to the fetus during pregnancy would be the most useful. But how could this be done safely given the vulnerable population being studied?

That’s where our article comes in. Our base article is one of the few larger trials looking at biochemical evidence of TNF inhibitor concentrations in cord blood, thus helping quantify drug transference from mother to fetus during pregnancy.2 In the study, all anti-TNF drugs were stopped at the time recommended by EULAR (typically between 20­ and 37 weeks of gestation).1 Results showed that adalimumab (n=25; stopped by week 20) was detected in 48% of cord blood samples; infliximab (n=14; stopped by week 20) was detected in 57% of cord blood samples; certolizumab (n=68; continued throughout pregnancy) was detected in 5.9% of cord blood samples; and etanercept (n=30; stopped prior to week 30) was not detected in any cold blood samples (lower limit of quantification 0.1 μg/mL).

The observation that detectable drug concentrations were measured in many of the samples is reason to pause and ask: What is the clinical significance of this finding?

The concentration ratio of TNF inhibitors in cord blood to maternal blood ranged from 0.01 to 0.062, depending on the agent, suggesting very low levels of transfer. The clinical significance of these levels of anti-TNF agents may not be fully established, but we have plenty of evidence to suggest the levels are safe. Studies have shown concentrations of 0.1 μg/mL can bind all circulating TNF, suggesting this level as a cutoff value for clinically relevant concentrations.3

Infants born to mothers on anti-TNF therapy have been studied more extensively in inflammatory bowel disease (IBD) literature. Those studies have shown the use of biologic therapy during pregnancy does not affect infant response to vaccines or achievement of developmental milestones, or increase the risk of infection.4-6

Certolizumab is the anti-TNF treatment we all know and love because it’s safe during pregnancy. It’s known for its unique lack of immunoglobulin G (IgG) fragment crystallizable (Fc) region, which keeps it from binding to the placental Fc receptor and, thus, is not transferred across the placenta from mother to fetus.7 But what about etanercept? Previous studies suggest some transplacental transport via antibody Fc fragment, but our base article suggests a lack of significant placental transfer.8 Along with evidence suggesting little, if any, placental transfer during pregnancy when stopped prior to 30 weeks of gestation, this finding may elicit a stronger support for use of etanercept throughout pregnancy.

The ACR guideline is notably less specific than EULAR, grouping most TNF inhibitors—other than certolizumab—together into the same category, with the conditional recommendation to continue these treatments during the first and second trimesters and discontinue during the third trimester, several half-lives prior to delivery.9 Guidelines for pregnant patients with IBD on biologic therapy recommend continuing biologics throughout pregnancy without interruption.10 Instead of discontinuing therapy, providers typically adjust the final dosing prior to delivery to achieve a low estimated trough because this is associated with lower adverse pregnancy outcomes for both mother and baby.

Implications

The implications of this study for patients cannot be overstated. In this unique circumstance, in which providers are taking care of both the mother and baby, every decision matters. These results can help providers make specific, patient-centered recommendations for their patients when it comes to the use of TNF inhibitors during pregnancy. The methods used in this study serve as an example of how to further examine transference of biologics and other drugs from mother to fetus.

Although guidelines are a great resource for all patients and providers, this study gives us more detailed information to make specific and patient-centered decisions.

Chances in the Tournament

TNFi in Cord Blood takes medication management in pregnancy one step further by looking at the science behind the guidelines and even rocks the boat on some current recommendations. Additionally, it gives us biochemical evidence supporting their safe use during pregnancy.

Our article creates an excellent base for further research on the topic of safe medications during pregnancy and continuously improving recommendations for our patients, both large and small.


Lauren He, MD, is an internal medicine resident at University of Chicago Medicine.

Cuoghi Edens, MD, is an assistant professor of Internal Medicine & Pediatrics, Section of Rheumatology & Pediatric Rheumatology at University of Chicago Medicine.

References

  1. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 May;75(5):795–810.
  2. Ghalandari N, Kemper E, Crijns I. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis. 2021 Sep 7;annrheumdis-2021-221036.
  3. Berkhout LC, I’Ami MJ, Ruwaard J, et al. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med. 2019 Jan 30;11(477):eaat3356.
  4. Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018 Jan;16(1):99–105.
  5. De Lorenzo R, Ramirez GA, Punzo D, et al. Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol Res. 2020 Feb;152:104583.
  6. Tsao NW, Lynd LD, Sayre EC, et al. Use of biologics during pregnancy and risk of serious infections in the mother and baby: A Canadian population-based cohort study. BMJ Open. 2019 Feb 20;9(2):e023714.
  7. Mariette X, Froger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228–233.
  8. Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford). 2010 Nov;49(11):2225–2227.
  9. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020 Apr;72(4):529–556.
  10. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019 Apr;156(5):1508–1524.

Experience All of RheumMadness

During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to read the scouting reports. Check out the reports from each region:

Region: Cells

• Anti-NET Antibodies

• Cytokine Networks

• CAR-T Cells

• Pim Kinases

Region: Animal House

• Axolotl Limbs

• Dinosaur SpA

• Dalmatian Urate

• Dog Osteoarthritis

Region: Machines

• AI: JIA Subtypes

• AI: TNFi Response

• DECT in Gout

• PET in LVV

Region: People

• Reproductive Health Guide

• TNFi in Cord Blood

• Increasing +ANA

• False Positive MRI in Axial SpA

Don’t forget to submit your RheumMadness 2022 bracket by March 25. The winner of each match-up is decided by a seven-member Blue Ribbon Panel of rheumatologists. The panel will vote based on which topic they think is most important to patients, providers and researchers—both now and in the future. The more your picks match those of the panel, the more points you get. The tournament results will be released in four rounds from March 26–April 4. Prizes will be given to participants with the top scores in the following categories: 1) attending/APP, 2) fellow and 3) resident/medical student. The prize is a custom RheumMadness coffee mug and a lifetime of bragging rights.

Connect with RheumMadness by subscribing to the podcast and joining the conversation on Twitter, #RheumMadness. Learn on the RheumMadness website.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 | Multi-Page
Share: 

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:cord blooddrug transferencepregnancyRheumMadnessTNFitumor necrosis factor inhibitor (TNFi)

Related Articles
    Tasha Art; PureSolution / shutterstock.com

    RheumMadness: An Educational Tournament

    July 15, 2021

    Tasha Art; PureSolution / shutterstock.com RheumMadness is an online collaborative learning experience created to educate trainees, rheumatologists and the wider medical community about recent advances and important concepts in rheumatology. The project is funded by the Rheumatology Research Foundation Clinician Scholar Educator (CSE) Award and modeled after NephMadness, an educational initiative of the American Journal…

    Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report

    March 2, 2022

    Rheumatologists play a critical role in the reproductive health of their patients, but only half of rheumatologists currently ask their patients about reproductive health or family planning issues. A new guideline seeks to change that.

    An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

    February 8, 2022

    According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.

    Beyond Trial & Error: RheumMadness 2022 AI: TNFi Response Scouting Report

    February 14, 2022

    As the capabilities of machine learning and artificial intelligence improve, rheumatologists have access to more data than ever, which may enable them to better predict which patients will respond to specific treatments, such as tumor necrosis factor inhibitors.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences